West Pharmaceutical Services (WST) Q2 2025 Earnings Call July 24, 2025 08:00 AM ET Company ParticipantsJohn Sweeney - VP - IREric Green - Chair, President & CEOBernard Birkett - SVP & CFOPaul Knight - Managing DirectorMichael Ryskin - Managing DirectorMac Etoch - Senior Research AssociateDaniel Markowitz - Vice PresidentDoug Schenkel - MD - Life Science Tools & DiagnosticsSalem Salem - VP - Equity ResearchThomas DeBourcy - PrincipalPatrick Donnelly - Managing DirectorTucker Remmers - Senior AssociateConfere ...

ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at the 8th Annual OIS Retina Innovation Summit being held on July 29, 2025 in Long Beach CA. Details for the presentations are as follows:Session: Innovation Showcase Presenter: Bob Jahr, Chief Executive Officer of Outlook TherapeuticsDate and Time: Tuesday, J ...

West Pharmaceutical Services (WST) Q2 2025 Earnings Call July 24, 2025 08:00 AM ET Speaker0Good day and thank you for standing by. Welcome to the Q2 twenty twenty five West Pharmaceutical Services Earnings Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone.Please be advised that today's conference is being recorded. I would now l ...

NEW YORK, July 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Biohaven Ltd. (NYSE: BHVN).Shareholders who purchased shares of BHVN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/biohaven-ltd-loss-submission-form/?id=157774&from=4CLASS PERIOD: March 24, 2023 to May 14, 20 ...

Agreement with Digital Offering Advances Company's plan to assess innovative treasury-backed financing pathsLA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into an engagement agreement with Digital Offering LLC, a FINRA- and SEC-registered broker-dealer, to serve as its exclusive placement agent in connection with the company ...

Core Points - Mersana Therapeutics, Inc. announced a 1-for-25 reverse stock split effective July 25, 2025, aimed at increasing the per-share market price to comply with Nasdaq listing requirements [1][2] - The reverse stock split will reduce the number of outstanding shares from approximately 124.8 million to about 5.0 million, without changing the number of authorized shares or par value [4] - The company's common stock will begin trading on a split-adjusted basis on July 28, 2025, under the existing ticker "MRSN" [3] Company Overview - Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, addressing high unmet medical needs [1][8] - The company has proprietary ADC platforms, including Dolasynthen and Immunosynthen, with a pipeline of product candidates targeting various cancers [8] - Notable candidates in the pipeline include Emi-Le (emiltatug ledadotin) targeting B7-H4 and XMT-2056 targeting a novel epitope of HER2 [8]

SEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its second quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, August 7, 2025, at 8:30 AM EDT. To access the webcast, ...

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action. Investors have until August 25, 2025, to as ...

NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This designation complements CAN-2409’s existing U.S. Food and Drug Administration (FDA) Orpha ...

BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answe ...